Accord BioPharma Launches Two Denosumab Biosimilars
RALEIGH, N.C., July 23, 2026 Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, has announced the commercial...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
RALEIGH, N.C., July 23, 2026 Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, has announced the commercial...
RICHMOND, Va., July 23, 2026 Alps Dx has announced the launch of Xpressorâ„¢ by Alps Dx, an innovative filtration...
WASHINGTON, D.C., July 22, 2026 The U.S. Food and Drug Administration (FDA) has announced two significant regulatory actions aimed...
